ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2022
Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging.
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07635524 (A Two Center Phase 2 Trial of 61Cu-noDAGa-PSMA I&T), which is not on this map. Cited by 66 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Two Center Phase 2 Trial of 61Cu-noDAGa-PSMA I&T (61Cu-NU101) for Patients With Prostate Cancer
Who cites it
66 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Liver Background Uptake of Prostate-specific Membrane Antigen-targeted PET Radiotracers: A Systematic Review and Meta-Analysis.Radiology. Imaging cancer · 2026Pooled it
- The role of PSMA PET/CT in staging patients with intermediate-risk prostate cancer.BJU international · 2026Pooled it
- Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use ofClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Guideline
- Ablative radiotherapy in castration-resistant prostate cancer.BJU international · 2026Trial
- Comparison of [European journal of nuclear medicine and molecular imaging · 2026Trial
- Pharmacokinetics and dosimetry of [Annals of nuclear medicine · 2025Trial
- Trial
- Multimodal artificial intelligence in prostate cancer: integrating multiparametric MRI with clinicopathological, molecular, and functional imaging data.Abdominal radiology (New York) · 2026Review
- Review
- Can Tc-99m-PSMA SPECT/CT Be Used as Accessible Alternative for Diagnosis of Biochemically Recurrent Prostate Cancer? A Prospective Study.Diagnostics (Basel, Switzerland) · 2026Article
- Dynamic 18 F-PSMA-1007 PET-CT kinetics as a prognostic marker in newly diagnosed prostate cancer: a prospective pilot study.World journal of urology · 2026Article
- Multidisciplinary expert consensus on treatment intensification in metastatic androgen pathway modulation-sensitive prostate cancer: a case-based RAND/UCLA analysis.Drugs in context · 2026Review
- Impact of PSMA PET Staging on Initial Treatment in Newly Diagnosed Prostate Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Oncologic outcomes of salvage radiotherapy and lymphadenectomy for positron emission tomography-positive lymph nodes in biochemical recurrence: A systematic review to inform treatment decisions.Prostate international · 2025Review
- Guideline of guidelines: PSMA PET in staging newly diagnosed intermediate-risk prostate cancer.BJU international · 2025Review
- Triple Tumors Uncovered: Insights fromMolecular imaging and radionuclide therapy · 2025Article
- Long Axial Field-of-view PET: A New Era of Quantitative PET Imaging for Theranostic Applications in Clinic.PET clinics · 2025Review
- MDT perspective: innovative applications of stereotactic body radiation therapy in metastatic castration-resistant prostate cancer.Prostate cancer and prostatic diseases · 2025Review
- The appropriateness of PSMA PET/CT in newly diagnosed unfavorable intermediate-risk prostate cancer patients-towards a tumor volume-based risk stratification.Prostate cancer and prostatic diseases · 2025Article
- ARTnet Perspectives and Contributions to Theranostics.World journal of nuclear medicine · 2025Review
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.